The Growth Hormone Hypothesis - 2005 Revision

J. Frystyk

doi:10.1055/s-2005-861362

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000025.xml

Share / Bookmark

Facebook X Linkedin Weibo

Download PDF

Horm Metab Res 2005; 37: 44-48
DOI: 10.1055/s-2005-861362

Review

The Growth Hormone Hypothesis - 2005 Revision

J. Frystyk¹

¹ Medical Research Laboratories & Medical Department M, Aarhus University Hospital, Aarhus, Denmark

Further Information

Publication History

Received 8 December 2004

Accepted after Revision 21 February 2005

Publication Date:
25 May 2005 (online)

Also available at

Abstract
Full Text
References

Buy Article Permissions and Reprints

Abstract

Growth hormone (GH) and insulin-like growth factor I (IGF-I) have been suggested to play a leading role in the development of diabetic retinopathy for more than three decades [1]. At the time of writing, there is a substantial amount of experimental data supporting a role of GH and IGF-I in the development of diabetic retinopathy, whereas clinical trials have yielded variable results. However, both hormones, with IGF-I as the ringleader, remain under suspicion as pathogenic agents. This mini-review will discuss the current literature on the possible involvement of GH and IGF-I in the development of diabetic retinopathy. Hopefully, the reader will agree that although the indictment against GH and IGF-I has celebrated its 34^th anniversary, it is still attractive from a scientific point of view.

Key words

Proliferative diabetic retinopathy - GH - IGF-I - Pegvisomant - Somatostatin analogues - GH hypothesis

References

1 Frank R N. Diabetic retinopathy. N Engl J Med. 2004; 350 48-58

Crossref PubMed Search in Google Scholar
2 Lundbæk K, Jensen V A, Olsen T S, Ørskov H, Christensen N J, Johansen K, Hansen A P, Østerby R. Diabetes, diabetic angiopathy, and growth hormone. Lancet. 1970; 2 131-133

PubMed Search in Google Scholar
3 Poulsen J E. Recovery from retinopathy in a case of diabetes with Simmonds' disease. Diabetes. 1953; 2 7-12

PubMed Search in Google Scholar
4 Ørskov H, Thomsen H G, Yde H. Wick chromatography for rapid and reliable immunoassay of insulin, glucagon and growth hormone. Nature. 1968; 219 193-195

PubMed Search in Google Scholar
5 Luft R, Olivecrona H, Ikkos D, Kornerup T, Ljunggren H. Hypophysectomy in man; further experiences in severe diabetes mellitus. Br Med J. 1955; 24 752-756

PubMed Search in Google Scholar
6 Sharp P S, Fallon T J, Brazier O J, Sandler L, Joplin G F, Kohner E M. Long-term follow-up of patients who underwent yttrium-90 pituitary implantation for treatment of proliferative diabetic retinopathy. Diabetologia. 1987; 30 199-207

Crossref PubMed Search in Google Scholar
7 Wright A D, Kohner E M, Oakley N W, Hartog M, Joplin G F, Fraser T R. Serum growth hormone levels and the response of diabetic retinopathy to pituitary ablation. Br Med J. 1969; 2 346-348

PubMed Search in Google Scholar
8 Das A, McGuire P G. Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Prog Retin Eye Res. 2003; 22 721-748

Crossref PubMed Search in Google Scholar
9 Rymaszewski Z, Cohen R M, Chomczynski P. Human growth hormone stimulates proliferation of human retinal microvascular endothelial cells in vitro. Proc Natl Acad Sci USA. 1991; 88 617-621

PubMed Search in Google Scholar
10 Grant M B, Guay C, Marsh R. Insulin-like growth factor I stimulates proliferation, migration, and plasminogen activator release by human retinal pigment epithelial cells. Curr Eye Res. 1990; 9 323-335

PubMed Search in Google Scholar
11 Spoerri P E, Ellis E A, Tarnuzzer R W, Grant M B. Insulin-like growth factor: receptor and binding proteins in human retinal endothelial cell cultures of diabetic and non-diabetic origin. Growth Horm IGF Res. 1998; 8 125-132

PubMed Search in Google Scholar
12 Smith L E, Kopchick J J, Chen W, Knapp J, Kinose F, Daley D, Foley E, Smith R G, Schaeffer J M. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science. 1997; 276 1706-1709

Crossref PubMed Search in Google Scholar
13 Poulaki V, Joussen A M, Mitsiades N, Mitsiades C S, Iliaki E F, Adamis A P. Insulin-like growth factor I plays a pathogenetic role in diabetic retinopathy. Am J Pathol. 2004; 165 457-469

Crossref PubMed Search in Google Scholar
14 Smith L E, Shen W, Perruzzi C, Soker S, Kinose F, Xu X, Robinson G, Driver S, Bischoff J, Zhang B, Schaeffer J M, Senger D R. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor I receptor. Nat Med. 1999; 5 1390-1395

Search in Google Scholar
15 Poulaki V, Qin W, Joussen A M, Hurlbut P, Wiegand S J, Rudge J, Yancopoulos G D, Adamis A P. Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1 alpha and VEGF. J Clin Invest. 2002; 109 805-815

Crossref PubMed Search in Google Scholar
16 Chantelau E, Eggert H, Seppel T, Schonau E, Althaus C. Elevation of serum IGF-1 precedes proliferative diabetic retinopathy in Mauriac's syndrome [letter]. Br J Ophthalmol. 1997; 81 169-170

PubMed Search in Google Scholar
17 Hyer S L, Sharp P S, Sleightholm M, Burrin J M, Kohner E M. Progression of diabetic retinopathy and changes in serum insulin-like growth factor I (IGF-I) during continuous subcutaneous insulin infusion (CSII). Horm Metab Res. 1989; 21 18-22

PubMed Search in Google Scholar
18 Grant M, Russell B, Fitzgerald C, Merimee T J. Insulin-like growth factors in vitreous. Studies in control and diabetic subjects with neovascularization. Diabetes. 1986; 35 416-420

PubMed Search in Google Scholar
19 Burgos R, Mateo C, Canton A, Hernandez C, Mesa J, Simo R. Vitreous levels of IGF-I, IGF binding protein 1, and IGF binding protein 3 in proliferative diabetic retinopathy: a case-control study. Diabetes Care. 2000; 23 80-83

PubMed Search in Google Scholar
20 Meyer Schwickerath R, Pfeiffer A, Blum W F, Freyberger H, Klein M, Losche C, Rollmann R, Schatz H. Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects. J Clin Invest. 1993; 92 2620-2625

Crossref PubMed Search in Google Scholar
21 Spranger J, Buhnen J, Jansen V, Krieg M, Meyer-Schwickerath R, Blum W F, Schatz H, Pfeiffer A F. Systemic levels contribute significantly to increased intraocular IGF-I, IGF-II and IGF-BP3 in proliferative diabetic retinopathy. Horm Metab Res. 2000; 32 196-200

PubMed Search in Google Scholar
22 Waldbillig R J, Jones B E, Schoen T J, Moshayedi P, Heidersbach S, Bitar M S, van Kuijk F J, de Juan E, Kador P, Chader G J. Vitreal insulin-like growth factor binding proteins (IGFBPs) are increased in human and animal diabetics. Curr Eye Res. 1994; 13 539-546

PubMed Search in Google Scholar
23 Boulton M, Gregor Z, McLeod D, Charteris D, Jarvis Evans J, Moriarty P, Khaliq A, Foreman D, Allamby D, Bardsley B. Intravitreal growth factors in proliferative diabetic retinopathy: correlation with neovascular activity and glycaemic management. Br J Ophthalmol. 1997; 81 228-233

Crossref PubMed Search in Google Scholar
24 Hopkins K D, Brart D O, Russell Jones D L, Chignell A H, Sönksen P H. Insulin-like growth factor binding protein-1 levels in diabetic proliferative retinopathy. Horm Metab Res. 1993; 25 331-332

PubMed Search in Google Scholar
25 Arnold D R, Moshayedi P, Schoen T J, Jones B E, Chader G J, Waldbillig R J. Distribution of IGF-I and -II, IGF binding proteins (IGFBPs) and IGFBP mRNA in ocular fluids and tissues: potential sites of synthesis of IGFBPs in aqueous and vitreous. Exp Eye Res. 1993; 56 555-565

Crossref PubMed Search in Google Scholar
26 Pfeiffer A, Spranger J, Meyer-Schwickerath R, Schatz H. Growth factor alterations in advanced diabetic retinopathy: a possible role of blood retina barrier breakdown. Diabetes. 1997; 46 Suppl 2 S26-S30

PubMed Search in Google Scholar
27 Hyer S L, Sharp P S, Brooks R A, Burrin J M, Kohner E M. A two-year follow-up study of serum insulinlike growth factor-I in diabetics with retinopathy. Metabolism. 1989; 38 586-589

Crossref PubMed Search in Google Scholar
28 Acerini C L, Patton C M, Savage M O, Kernell A, Westphal O, Dunger D B. Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus. Lancet. 1997; 350 1199-1204

Crossref PubMed Search in Google Scholar
29 Lauszus F F, Klebe J G, Bek T, Flyvbjerg A. Increased serum IGF-I during pregnancy is associated with progression of diabetic retinopathy. Diabetes. 2003; 52 852-856

Crossref PubMed Search in Google Scholar
30 Grant M B, Caballero S. Somatostatin analogues as drug therapies for retinopathies. Drugs Today (Barc). 2002; 38 783-791

Crossref PubMed Search in Google Scholar
31 Kopchick J J, Parkinson C, Stevens E C, Trainer P J. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev. 2002; 23 623-646

PubMed Search in Google Scholar
32 Grant M B, Caballero S, Millard W J. Inhibition of IGF-I and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: a potential treatment for ocular neovascularization. Regul Pept. 1993; 48 267-278

Crossref PubMed Search in Google Scholar
33 Hyer S L, Sharp P S, Brooks R A, Burrin J M, Kohner E M. Continuous subcutaneous octreotide infusion markedly suppresses IGF-I levels whilst only partially suppressing GH secretion in diabetics with retinopathy. Acta Endocrinol (Copenh). 1989; 120 187-194

PubMed Search in Google Scholar
34 Kirkegaard C, Nørgaard K, Snorgaard O, Bek T, Larsen M, Lund-Andersen H. Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in Type I (insulin-dependent) diabetes mellitus. Acta Endocrinol (Copenh). 1990; 122 766-772

PubMed Search in Google Scholar
35 Shumak S L, Grossman L D, Chew E, Kozousek V, George S R, Singer W, Harris A G, Zinman B. Growth hormone suppression and nonproliferative diabetic retinopathy: a preliminary feasibility study. Clin Invest Med. 1990; 13 287-292

PubMed Search in Google Scholar
36 McCombe M, Lightman S, Eckland D J, Hamilton A M, Lightman S L. Effect of a long-acting somatostatin analogue (BIM23014) on proliferative diabetic retinopathy: a pilot study. Eye. 1991; 5 (Pt 5) 569-575

PubMed Search in Google Scholar
37 Mallet B, Vialettes B, Haroche S, Escoffier P, Gastaut P, Taubert J P, Vague P. Stabilization of severe proliferative diabetic retinopathy by long-term treatment with SMS 201 - 995. Diabete Metab. 1992; 18 438-444

PubMed Search in Google Scholar
38 Boehm B O, Lang G K, Jehle P M, Feldman B, Lang G E. Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm Metab Res. 2001; 33 300-306

Thieme Connect PubMed Search in Google Scholar
39 Grant M B, Mames R N, Fitzgerald C, Hazariwala K M, Cooper-DeHoff R, Caballero S, Estes K S. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care. 2000; 23 504-509

PubMed Search in Google Scholar
40 Growth Hormone Antagonist for Proliferative Diabetic Retinopathy Study Group . The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy. Ophthalmology. 2001; 108 2266-2272

Crossref PubMed Search in Google Scholar
41 Holt R I, Simpson H L, Sönksen P H. The role of the growth hormone-insulin-like growth factor axis in glucose homeostasis. Diabet Med. 2003; 20 3-15

Crossref PubMed Search in Google Scholar
42 Powell E D, Frantz A G, Rabkin M T, Field R A. Growth hormone in relation to diabetic retinopathy. N Engl J Med. 1966; 275 922-925

PubMed Search in Google Scholar
43 Blickle J F, Schlienger J L, de Laharpe F, Stephan F. Growth hormone response to thyrotropin-releasing hormone in insulin-dependent diabetics with or without severe microvascular lesions. Diabete Metab. 1982; 8 197-201

PubMed Search in Google Scholar
44 Sharp P S, Foley K, Vitelli F, Maneschi F, Kohner E M. Growth hormone response to hyperinsulinaemia in insulin-dependent diabetics. Comparison of patients with and without retinopathy. Diabet Med. 1984; 1 55-58

PubMed Search in Google Scholar
45 Kaneko K, Komine S, Maeda T, Ohta M, Tsushima T, Shizume K. Growth hormone responses to growth-hormone-releasing hormone and thyrotropin-releasing hormone in diabetic patients with and without retinopathy. Diabetes. 1985; 34 710-713

PubMed Search in Google Scholar
46 Almqvist E G, Groop L C, Manhem P J. Growth hormone response to the insulin tolerance and clonidine tests in type 1 diabetes. Scand J Clin Lab Invest. 1999; 59 375-382

PubMed Search in Google Scholar
47 Savage M O, Camacho-Hubner C, Dunger D B. Therapeutic applications of the insulin-like growth factors. Growth Horm IGF Res. 2004; 14 301-308

PubMed Search in Google Scholar
48 Frystyk J. Free insulin-like growth factors-measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm IGF Res. 2004; 14 337-375

Crossref PubMed Search in Google Scholar
49 Johansen K, Hansen Aa P. Diurnal serum growth hormone levels in poorly and well controlled juvenile diabetics. Diabetes. 1971; 20 239-245

PubMed Search in Google Scholar
50 The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group . Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000; 342 381-389

Crossref PubMed Search in Google Scholar
51 Kjeldsen H, Hansen A P, Lundbæk K. Twenty-four-hour serum growth hormone levels in maturity-onset diabetics. Diabetes. 1975; 24 977-982

PubMed Search in Google Scholar
52 Scacchi M, Pincelli A I, Cavagnini F. Growth hormone in obesity. Int J Obes Relat Metab Disord. 1999; 23 260-271

Crossref PubMed Search in Google Scholar
53 Lindström T, Nyström F H, Olsson A G, Ottosson A-M, Arnqvist H J. The lipoprotein profile differs during insulin treatment alone and combination therapy with insulin and sulphonylureas in patients with Type 2 diabetes mellitus. Diabetic Medicine. 1999; 16 820-826

Crossref PubMed Search in Google Scholar
54 Gibson J M, Westwood M, Crosby S R, Gordon C, Holly J M, Fraser W, Anderson C, White A, Young R J. Choice of treatment affects plasma levels of insulin-like growth factor-binding protein-1 in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1995; 80 1369-1375

Crossref PubMed Search in Google Scholar
55 Clauson P G, Brismar K, Hall K, Linnarsson R, Grill V. Insulin-like growth factor I and insulin-like growth factor binding protein-1 in a representative population of type 2 diabetic patients in Sweden. Scand J Clin Lab Invest. 1998; 58 353-360

PubMed Search in Google Scholar
56 Frystyk J, Ivarsen P, Skjærbæk C, Flyvbjerg A, Pedersen E B, Ørskov H. Serum-free insulin-like growth factor I correlates with clearance in patients with chronic renal failure. Kidney Int. 1999; 56 2076-2084

Crossref PubMed Search in Google Scholar
57 Dills D G, Moss S E, Klein R, Klein B E, Davis M. Is insulin-like growth factor I associated with diabetic retinopathy?. Diabetes. 1990; 39 191-195

PubMed Search in Google Scholar
58 Feldmann B, Jehle P M, Mohan S, Lang G E, Lang G K, Brueckel J, Boehm B O. Diabetic retinopathy is associated with decreased serum levels of free IGF-I and changes of IGF-binding proteins. Growth Horm IGF Res. 2000; 10 53-59

PubMed Search in Google Scholar
59 Frystyk J, Bek T, Flyvbjerg A, Skjærbæk C, Ørskov H. The relationship between the circulating IGF system and the presence of retinopathy in Type 1 diabetic patients. Diabet Med. 2003; 20 269-276

Crossref PubMed Search in Google Scholar
60 Hyer S L, Sharp P S, Brooks R A, Burrin J M, Kohner E M. Serum IGF-I concentration in diabetic retinopathy. Diabet Med. 1988; 5 356-360

PubMed Search in Google Scholar
61 Janssen J A, Jacobs M L, Derkx F H, Weber R F, van der Lely A J, Lamberts S W. Free and total insulin-like growth factor I (IGF-I), IGF-binding protein-1 (IGFBP-1), and IGFBP-3 and their relationships to the presence of diabetic retinopathy and glomerular hyperfiltration in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1997; 82 2809-2815

Crossref PubMed Search in Google Scholar
62 Merimee T J, Zapf J, Froesch E R. Insulin-like growth factors. Studies in diabetics with and without retinopathy. N Engl J Med. 1983; 309 527-530

PubMed Search in Google Scholar
63 Wang Q, Dills D G, Klein R, Klein B E, Moss S E. Does insulin-like growth factor I predict incidence and progression of diabetic retinopathy?. Diabetes. 1995; 44 161-164

PubMed Search in Google Scholar
64 Frystyk J, Skjærbæk C, Vestbo E, Fisker S, Ørskov H. Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes. Diabetes Metab Res Rev. 1999; 15 314-322

Crossref PubMed Search in Google Scholar

J. Frystyk, M. D., Ph. D., D. M. Sc.

Medical Research Laboratory, Aarhus University Hospital

Norrebrogade 44 · 8000 Aarhus C · Denmark

Email: jan@frystyk.dk